Richard M. Goldberg

Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

Marlo Blazer, Christina Wu, Richard M. Goldberg et al. · Annals of Surgical Oncology · 2014 · 249 citations · Full text

Surgical Oncology, Locally Advanced Unresectable, Pancreatic Cancer +10

Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2

Sigurdís Haraldsdóttir, Wendy L. Frankel, Sylvia Einarsdottir et al. · Nature Communications · 2017 · 120 citations · Full text

Genetics, Genetic Epidemiology, Molecular Biology +17

Prostate cancer incidence in males with Lynch syndrome

Sigurdís Haraldsdóttir, Heather Hampel, Lai Wei et al. · Genetics in Medicine · 2014 · 104 citations · Full text

Urology, Prostate Cancer Incidence, Cancer Epidemiology +5

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

Ghassan K. Abou‐Alfa, Donna Niedzwieski, Jennifer J. Knox et al. · Journal of Clinical Oncology · 2016 · 103 citations

Pathology, Doxorubicin Versus Sorafenib, Pharmacotherapy +20

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

Frank A. Sinicrope, Michelle R. Mahoney, Harry H. Yoon et al. · Clinical Cancer Research · 2015 · 88 citations · Full text